Compare 10X Genomics Inc (TXG) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Wendys Co — how do they compare? 10X Genomics Inc trades at $59.15 (market cap $7.61B), while Wendys Co trades at $7.7 (market cap $1.44B). The key difference: 10X Genomics Inc is far larger — about 5.3× Wendys Co's market cap, and Wendys Co pays a 3.71% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | WEN | |
|---|---|---|
Market Cap | $7.61B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $58.57 | $10.68 |
52-Week Low | $11.34 | $6.17 |
Enterprise Value | $7.14B | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Wendy's stock (WEN) trades at $7.30, down 5.07% amid significant operational challenges. The company faces declining U.S. traffic, a 50% dividend cut, and loss of its position as America's second-largest burger chain to Burger King. Despite beating Q2 2026 EPS estimates ($0.18 vs. $0.16 expected), revenue trends remain weak with profit margins contracting from 7.58% in 2025 to 5.72% projected for 2026. Technical indicators show bearish momentum with key support at $7.00.
The outlook remains challenging as new CEO Bob Wright implements a turnaround strategy. While valuation appears reasonable (P/E 11.44, P/S 0.65), execution risks are elevated given competitive pressures and $2.66 billion debt load. Analyst sentiment is mixed with 62.75% hold ratings, reflecting uncertainty about the company's ability to regain market share and improve franchisee economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
